API Synthesis and Manufacturing, Large Molecule

Reig Jofre and Leanbio Form Joint Venture to Develop Biosimilars

April 05, 2018

The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.

Unlocking the Best Solution for API Sourcing

April 02, 2018

CMOs/CDMOs that are easy to work with, have demonstrated performance track records, and plan for the future are preferred.

Helix BioPharma Partners with ProMab on CAR-T Therapies

March 23, 2018

The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.

Wuxi Biologics to Install Large-Scale Single-Use Bioreactor

March 22, 2018

The company plans to install 4000-L disposable bioreactors from ABEC at its new commercial manufacturing facility in Wuxi city, China.

FDA: Early Stage Drug Development Costs Trigger Higher Drug Costs

March 02, 2018

Drug companies must consider all factors impacting the cost of drugs, including high costs of early development stages.

Small Volumes, Big Challenges

March 02, 2018

Highly complex APIs developed to treat rare and orphan diseases present big technical questions for contract developers.

Samsung BioLogics Gets $148-Million Contract for New Manufacturing Plant

February 23, 2018

The contract development and manufacturing organization has entered it first manufacturing contract worth $148 million for its recently completed Plant 3 facility.

Ferring to Invest in New Biotech Center

February 14, 2018

Ferring Pharmaceuticals will expand its biologics capabilities at its headquarters and manufacturing site in Saint-Prex, Switzerland.

Acquity Arc Bio System Improves Bioseparation Analytical Methods

January 31, 2018

Pharmaceutical Technology's In the Lab eNewsletter

The new Acquity Arc Bio System by Waters is specifically engineered to enable efficient transfer and improvement of bioseparation analytical methods.

Sanofi to Acquire Ablynx in $4.8-Billion Deal

January 30, 2018

The acquisition will strengthen Sanofi's R&D strategy and expands its franchise for rare blood disorders.